Coronary Trials

  • PRECISE

A prospective, pragmatic, randomized clinical trial of the comparative effectiveness of diagnostic evaluation strategies for stable coronary artery disease, to be performed in outpatient settings, including primary care and cardiology practices.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT03702244

Peripheral Trials

  • CREST II

Carotid revascularization and medical management for asymptomatic carotid stenosis trial

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT02089217

  • DISRUPT PAD

Randomized study of the Shockwave Medical Peripheral Lithoplasty® System used in combination with DCB versus standard balloon angioplasty used in combination with DCB to treat moderate and severely calcified femoropopliteal arteries (Disrupt PAD III).

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT02923193?term=disrupt+pad&rank=3

  • TRANSCEND DCB

The Randomized And Controlled Noninferiority Trial to Evaluate Safety and Clinical Efficacy of the SurVeil™ Drug-Coated Balloon iN the Treatment of Subjects With Stenotic Lesions of the Femoropopliteal Artery Compared to the Medtronic IN.PACT® Admiral® Drug-Coated Balloon.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT03241459?term=Transcend+DCB&rank=1

  • DETOUR II

A prospective, single-arm, multi-center, international, non-randomized, safety and effectiveness clinical investigation of the PQ Bypass system.  The PQ Bypass System is intended to improve blood flow in patients with symptomatic peripheral arterial disease due to >15 cm long occlusions and diffuse stenosis of femoropopliteal arteries, including in-stent re-stenosis, with reference vessel diameters ranging from 5.0 – 6.7 mm.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT03119233

Structural Heart Trials

  • EARLY TAVR

To establish the safety and effectiveness of the Edwards SAPIEN 3 (Edwards Lifesciences, Irvine, California) Transcatheter Heart Valve (THV) compared with clinical surveillance (CS) in asymptomatic patients with severe, calcific aortic stenosis

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT03042104?term=early+tavr&draw=1&rank=1

 

  • AMPLATZER™ PFO Occluder Post-Approval Study

AMPLATZER™ PFO Occluder Post Approval Clinical Study is a single arm, multi-center study to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder, in a post approval setting, in patients with a PFO who have had a cryptogenic stroke confirmed by a study neurologist.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT03309332

 

  • ASAP-TOO

A prospective, randomized, multi-center, global investigation to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device (including the post-implant medication regimen) with non-valvular atrial fibrillation who are deemed not suitable for anti-coagulation therapy to reduce the risk of stroke.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT02928497

 

  • WATCH-TAVR

A prospective, multicenter, randomized controlled trial, to evaluate the safety and effectiveness of the left atrial appendage occlusion with WATCHMAN Device in prevention of stroke and bleeding in patients with atrial fibrillation (AF) undergoing transcatheter aortic valve replacement (TAVR).

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT03173534

 

  • JENAVALVE

This study will examine the use of TAVR (Transcatheter Aortic Valve Replacement), which is a minimally invasive procedure designed to replace the aortic valve inside the heart. The JenaValve Pericardial TAVR System will be examined in this clinical study for aortic valve replacement.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/study/NCT02732704

 

  • ACURATE IDE

A prospective, multicenter trial designed to evaluate the safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for TAVR in subjects who have sever native aortic stenosis and are indicated for TAVR.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

Website pending…

 

  • AltaValve EFS

Prospective, single-arm, multicenter study to evaluate the safety and performance of the AltaValve for the treatment of moderate to severe or severe mitral valve regurgitation in subjects who are considered high risk for mortality and morbidity from conventional open-heart surgery.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT03997305

 

  • SUMMIT

Prospective, controlled, multicenter clinical investigation of the Tendyne Mitral Valve System for the treatment of eligible subjects with symptomatic, severe, mitral regurgitation.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

Website pending…

EP Trials

  • ARTESIA

Prospective, randomized, parallel group, double-blind trial To determine if the use of apixaban in patients with SCAF will reduce the incidence of stroke and systemic embolism compared to aspirin.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT01938248?term=artesia&draw=1&rank=1

  • SMART CRT

SMART CRT is a prospective, double-blind, multicenter, international, randomized controlled trial. The primary objective is to show the benefit of SmartDelay™ in patients with a prolonged RV-LV interval.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT03075215?term=smart+crt&rank=2

  • PREEMPT

A global, multi-center, post-market, prospective, non-randomized study, to collect device and clinical event data to evaluate extended applications of the HeartLogic™ Heart Failure Diagnostic (HeartLogic) in a broad spectrum of heart failure (HF) patients with an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D).

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

  • SOLVE CRT

A prospective, multi-center, randomized, controlled, double blinded, pivotal trial to study the safety and efficacy of the WiSE-LV System for Cardiac Re-synchronization Therapy. The WiSE-LV System is an implantable cardiac pacing system capable of delivering pacing energy to the left ventricle of the heart without using a pacing lead.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/study/NCT02922036

  • VISITAG SURPOINT

A prospective, non-randomized, post market clinical evaluation of the VISITAG SURPOINT™ Module with External Processing Unit (EPU) when used with STSF catheter and ST catheter compared to an historical control performance goal.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT03624881

  • INTERRUPT AF

A prospective, non-randomized, multicenter (global), post approval clinical study (PAS) to evaluate open irrigated ablation catheters with high resolution mapping to treat paroxysmal atrial fibrillation.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT03729830

  • aMAZE

A prospective, multicenter, randomized (2:1) controlled study to evaluate the safety and effectiveness of the LARIAT System to percutaneously isolate and ligate the Left Atrial Appendage from the left atrium as an adjunct to planned pulmonary vein isolation (PVI) catheter ablation in the treatment of subjects with symptomatic persistent or longstanding persistent atrial fibrillation.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT02513797

  • EV-ICD

Designed to demonstrate safety and efficacy of the Extravascular Implantable Cardioverter Defibrillator (EV ICD) System.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT04060680

Heart Failure Trials

  • CONNECT-HF

 This trial will be a large-scale, pragmatic, cluster-randomized clinical trial to evaluate the effect of 2 quality improvement (QI) initiatives compared with the usual care on heart failure (HF) outcomes and HF quality of care metrics in the year following discharge for participants hospitalized with acute HF and reduced ejection fraction (EF). All participants  in the trial will be consented for longitudinal follow-up as part of the CONNECT_HF registry on clinical outcomes, medication use, and participant-centered outcomes, including quality of life (QOL) assessments, at 6 weeks and 3, 6, 12 months after discharge.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT03035474?term=connect+hf&rank=1

Registry

  • THEME

A multicenter, prospective observation registry. By collecting prospective descriptive data, provide insight into disease defining characteristics resulting in the clinical decision to use TandemHeart for mechanical support and enhance knowledge of best practice regarding clinical management, weaning and removal/exit strategies.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT02326402

More Coming soon…..